New Hives Drug Remibrutinib BTK Inhibitor

hives-Remibrutinib-arthur-lubitz-immunologist-allergy-asthma-doctor-new-york

The introduction of Remibrutinib, a novel Bruton’s tyrosine kinase (BTK) inhibitor, marks a significant advancement in the therapeutic landscape for chronic urticaria (hives). Remibrutinib targets the BTK pathway, which plays a crucial role in the activation of mast cells and basophils, thus mitigating the inflammatory response characteristic of chronic urticaria. By inhibiting BTK, Remibrutinib effectively reduces the degranulation of these cells, leading to a decrease in the release of histamine and other pro-inflammatory mediators.

This BTK inhibition represents a novel mechanism of action distinct from the traditional antihistamines and corticosteroids currently employed in chronic urticaria management. Remibrutinib offers an alternative for patients who exhibit resistance to standard treatments, providing a new avenue for mitigating the symptoms of chronic urticaria and improving patient quality of life.

In parallel with advancements in chronic urticaria treatments, the field of asthma biologics has seen significant developments, particularly in the personalization of therapy based on specific biomarkers. Asthma, a heterogeneous disease characterized by chronic airway inflammation, can be categorized into different phenotypes, each necessitating a tailored therapeutic approach.

Key biomarkers such as fractional exhaled nitric oxide (FeNO), immunoglobulin E (IgE), and eosinophil count play critical roles in guiding the selection of biologic therapies. High eosinophil levels without concurrent allergic sensitization point towards an interleukin-5 (IL-5) driven pathway. In such cases, IL-5 inhibitors like Mepolizumab (Nucala) or Benralizumab (Fasenra) are preferred due to their efficacy in reducing eosinophilic inflammation and preventing exacerbations.

Conversely, patients presenting with high eosinophil counts coupled with elevated FeNO levels might benefit more from Dupilumab (Dupixent), which targets the IL-4/IL-13 pathway, addressing both eosinophilic inflammation and elevated FeNO. This dual mechanism makes Dupilumab particularly effective in managing severe asthma characterized by both eosinophilic and Type 2 inflammatory pathways.

For patients exhibiting high IgE levels, Omalizumab (Xolair) remains the biologic of choice. Omalizumab is an anti-IgE monoclonal antibody that binds to circulating IgE, preventing its interaction with the high-affinity IgE receptor on mast cells and basophils. This inhibition leads to a significant reduction in allergic inflammation and asthma exacerbations, particularly in patients with allergic asthma.

The emergence of Tezepelumab (Tezspire), a thymic stromal lymphopoietin (TSLP) inhibitor, offers a new option for patients with low Type 2 (T2) inflammatory profiles. Tezepelumab targets upstream inflammatory pathways, making it effective across a broader spectrum of asthma phenotypes, including those with low T2 biomarkers.

These advancements underscore the importance of a biomarker-driven approach in the management of asthma, allowing for more precise and effective treatment strategies. The selection of an appropriate biologic therapy hinges on a comprehensive assessment of a patient’s specific inflammatory profile, including FeNO, IgE, and eosinophil levels, to ensure optimal therapeutic outcomes. Dr. Arthur Lubitz will examine you, administer some tests, and asses what is the best treatment for your chronic urticaria.


If you need to book an appointment for your allergies or asthma, you can book your appointment online, or call (212) 247-7447.

Previous
Previous

The Role of Enzymes in Mast Cell Internal Processes

Next
Next

Asia Syndrome: Autoimmune/Inflammatory Syndrome Induced by Adjuvants and its Association with Hyaluronic Acid Fillers